{"result": {"id": "6bc34f57-a9f5-46aa-a547-fb0a07b22d79", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACEI is a type of medication used for treating hypertension and improving walking distance in patients with PAD and hypertension)\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB is a type of medication used as an initial antihypertensive treatment for patients with lower extremity arterial disease and hypertension)\n##\n(\"entity\"<|>CCB<|>ORGANIZATION<|>CCB is a type of medication used for initial combination antihypertensive therapy in patients with lower extremity arterial disease and hypertension)\n##\n(\"entity\"<|>β受体阻滞剂<|>ORGANIZATION<|>β受体阻滞剂 is a type of medication considered safe for use in patients with lower extremity arterial stenosis and hypertension)\n##\n(\"entity\"<|>利尿剂<|>ORGANIZATION<|>利尿剂 is a type of medication used for initial combination antihypertensive therapy in patients with lower extremity arterial disease and hypertension)\n##\n(\"relationship\"<|>ACEI<|>ARB<|>Both ACEI and ARB are recommended as initial antihypertensive treatments for patients with lower extremity arterial disease and hypertension<|>7)\n##\n(\"relationship\"<|>ACEI<|>CCB<|>ACEI and CCB are both used in the treatment of hypertension, with CCB being part of initial combination therapy<|>6)\n##\n(\"relationship\"<|>ACEI<|>β受体阻滞剂<|>Both ACEI and β受体阻滞剂 are medications used for treating hypertension in patients with lower extremity arterial disease<|>5)\n##\n(\"relationship\"<|>ARB<|>CCB<|>ARB and CCB are both used in the treatment of hypertension, with CCB being part of initial combination therapy<|>6)\n##\n(\"relationship\"<|>ARB<|>β受体阻滞剂<|>Both ARB and β受体阻滞剂 are medications used for treating hypertension in patients with lower extremity arterial disease<|>5)\n##\n(\"relationship\"<|>CCB<|>利尿剂<|>CCB and 利尿剂 are both used for initial combination antihypertensive therapy in patients with lower extremity arterial disease and hypertension<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558727, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 491, "prompt_tokens": 2413, "total_tokens": 2904, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 621}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 时 ,心血管风险最低 。对于存在下肢动脉疾病的高血  压患者 ,血压应控制在<140/90mmHg[581]  ,对于存在  糖尿病和 CKD 的患者 , 如能耐受 , 血压应控制 在<  130/80mmHg[581-582] 。\n　8.5.3   降压药选择   多项研究发现 ,ACEI具有改善 步行距离的作用 ,适合用于 PAD合并高血压的降压 治疗[583] 。荟萃分析及系统性评述显示,β受体阻滞剂 用于下肢动脉狭窄患者是安全的 。对于存在下肢动脉 疾病的高血压患者 ,ACEI或 ARB可作为初始降压治 疗药物 ,CCB及利尿剂可作为此类患者初始联合降压 治疗药物,β受体阻滞剂也可以考虑使用[581-582,584] 。\n　8.5.4  高血压合并颈动脉狭窄   对于伴有颈动脉狭  窄的高血压患者 ,血压控制目标尚存在争议 。 目前多  数指南推荐 ,血压控制在<140/90mmHg范围内 ,如  果患者同时合并糖尿病或 CKD,血压应控制在<130/\n　80mmHg。荟萃分析显示 , 双侧颈动脉狭窄程度 < 70%时 ,血压的升高与脑卒中风险是成正比的 。老年 双侧颈动脉狭窄程度>70%时 ,过度降压可能增加脑 缺血风险 ,宜适当放宽血压目标值 。降压药种类和剂 量的选择以及降压目标值应个体化 ,综合考虑药物、脑 卒中风险和患者血压调节能力三方面因素[391] 。对于 合并症状性颅外颈动脉狭窄的患者 , 除非患者处于脑 卒中超急性期 ,降压治疗可能是合理的。\n　　对于高血压合并颈动脉狭窄 ,多项研究表明长期  应用 CCB、ACEI治疗可降低患者的IMT,降低脑卒中  风险 。对于存在颈动脉粥样硬化的高血压患者 ,CCB 和 ACEI应 该 优 先 选 用 来 延 缓 颈 动 脉 粥 样 硬 化 的  进展[130] 。\n8.6   高血压合并肾脏疾病\n\n要点 8F   高血压合并肾脏疾病\n　　　·无蛋白尿的 CKD患者 ,在收缩压≥140mmHg 和/或舒张压 ≥90mmHg时启动降压药物治疗 , 血  压控制目标为<140/90mmHg( Ⅰ , A) , 如耐受 , 可  降到 130/80mmHg( Ⅱa,B) 。\n　　　·有蛋白尿的 CKD患者 ,在收缩压≥130mmHg 和/或舒张压 ≥80mmHg时启动降压药物治疗 , 血  压控制目标为<130/80mmHg( Ⅱa,B) 。\n　　　·无论是否合并糖尿病 ,有蛋白尿的 CKD患者 初始降压治疗应包括一种\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_d8f7d3fb8dbca055e8f4ab2a352c137973eec9a7b73a1bd43e923d22b823166e_v2"}